BUSINESS

Optimal tumor shrinkage rate in recurrent metastatic lymphoma patients

treated with JS001 in Phase I clinical trial

Source: Clinical trial result summary

Tumor load changed over time of recurrent metastatic lymphoma patients

treated with JS001 in Phase I clinical trial

Source: Clinical trial result summary

Safety. TRAEs were observed in 23 (95.8%) of patients. Among the 24 patients, Grade 3
TEAEs occurred in 4 patients (16.7%). Such TEAEs vary and include lung infection and
anemia, among others. No Grade 4 or 5 TEAEs were observed. One (4.2%) subject terminated
due to TEAE.

– 190 –

